YAMAHA
12.5.2023 04:01:33 CEST | Business Wire | Press release
In cooperation with the Delhi Board of School Education, Yamaha Corporation (below, "Yamaha") introduced Japanese-style instrumental music education using recorders for grade V students at ten public primary schools in India in April. Programs using recorders and keyboards have been offered as extra-curriculum activities at private primary schools in India since 2017, but this is the first time a program will be offered as part of public primary school classes. The program offered by Yamaha not only includes technical recorder instruction, but also incorporates groupwork and discussion within classes to cultivate mutual understanding. Preceding the start of the classes, music teacher training is being conducted with an emphasis on using a holistic learning approach. Yamaha aims to expand the program to more schools in Delhi in the future. “Introduction of Japanese-style music education in primary education in India” was adopted by MEXT as a 2022 EDU-Port Japan*1 Supported Project.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230511005424/en/
Classes at public primary school in India
About School Project
As a comprehensive musical instruments manufacturer, Yamaha has been promoting the advantages of music and instrumental music education to music education sites around the world. In particular, Yamaha’s School Project, which it has been developing principally in emerging countries since 2015, is an initiative with the aim of popularizing activities using music and musical instruments in public education to convey the joy of music and musical instruments. To date, Yamaha has provided a total of 2,020,000 children (as of March 2023) in seven countries—Malaysia, Indonesia, Vietnam, India, Brazil, the United Arab Emirates, and Egypt—with opportunities to learn instrumental music, helping to create an environment where children can enjoy music and playing musical instruments.
Through this activity, Yamaha aims to contribute to Goal 4: "Quality Education," Goal 10: “Reduced Inequalities,” Goal 16: “Peace, Justice and Strong Institutions,” and Goal 17: "Partnerships for the Goals" of the Sustainable Development Goals (SDGs), as well as to develop children's non-cognitive skills through music and instrumental music education and to formulate a business model for musical education activities tailored to the educational situation in schools around the world.
Comments from Yasuhiro Yonehara, First Secretary, Embassy of Japan in India
Walking through the streets of India, one can hear music along with the bustling of the city. In Bollywood films, actors can be seen dancing joyfully to upbeat songs. Indian people are very familiar with music, and I feel that music is an integral part of their lives. How exciting it is when Indian children pick up a recorder, an unfamiliar instrument, learn to play it and create music. I sincerely wish that this initiative, which is making this possible, will be a huge success.
*1 EDU-Port Japan is a “public-private, nationwide” initiative to introduce Japanese-style education overseas using the public-private collaborative platform, supported by Japan’s Ministry of Education, Culture, Sports, Science and Technology (MEXT).
https://www.yamaha.com/en/about/activities/school_project/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230511005424/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom